Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is affiliated to Sino Longitudinal Study on Cognitive Decline, SILCODE. To establish models of normal and pathological cognitive aging.To collect the longitudinal data of SCD population, to study the dynamic changes of brain networks so as to explore the progressive mechanisms of AD on brain networks and to construct a high-precision multi-modal model for early diagnosis.
This study is affiliated to Sino Longitudinal Study on Cognitive Decline, SILCODE. Alzheimer's disease (AD) is the most common cause of dementia, which severely injures multiple domains of cognitive functions in the aging people, bringing heavy burden to the society and families. Studying the cognitive brain damage mechanism of subjective cognitive decline (SCD), the preclinical stage of AD, would provide great opportunities for understanding the pathogenesis of AD and clinical value for early diagnosis and intervention in AD. The project intends to utilize amyloid-PET and FDG-PET for screening and then employ the comprehensive neuropsychological examination combined with multi-modal MRI neuroimaging techniques to study the brain functions and structures of the normal aging and SCD. The imaging data would be analyzed from several levels, including the cognitive dimensions, brain activation patterns, and especially functional and structural networks to establish the models of normal and pathological cognitive aging, which mainly be modulated by frontal-parietal control system. We aim to establish models of normal and pathological cognitive aging. Furthermore, the longitudinal data of SCD population would be collected to study the dynamic changes of brain networks so as to explore the progressive mechanisms of AD on brain networks and to construct a high-precision multi-modal model for early diagnosis
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Subjective cognitive decline, SCD | The inclusion criteria for SCD are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) failure to meet the following criteria for MCI. |
| |
| Normal control, NC | NC are individuals who have no self-report persistent decline in cognitive capacity, and with neither worry nor concern about their cognition. Without measurable cognitive impairment according to results of standard assessments. |
| |
| Mild cognitive impairment, MCI | MCI are defined by an actuarial neuropsychological method proposed by Jak and Bondi. Participants are considered to have MCI if any one of the following three criteria are met with a total Clinical Dementia Rating (CDR) score of 0.5 as well as failure to meet the criteria for dementia: (1) having impaired scores (defined as >1 SD below the age-corrected normative mean) on both measures within at least one cognitive domain (i.e., memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled; (3) the Functional Activities Questionnaire (FAQ) ≥9. |
| |
| Alzheimer's disease, AD | The diagnosis of AD syndrome is based on the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA) with a total CDR score of 1. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Neuropsychological scale | Diagnostic Test | Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on |
| Measure | Description | Time Frame |
|---|---|---|
| The altered volume pattern in SCD/SCD-plus with progression. |
| 5 years |
| The altered DTI pattern in SCD/SCD-plus with progression. |
| 5 years |
| The altered functional MRI pattern in SCD/SCD-plus with progression. | Resting state functional MRI blood-oxygen-level-dependent (fMRI BOLD) signal. | 5 years |
| The altered FDG-PET pattern in SCD/SCD-plus with progression. | Global SUVR change of brain of FDG-PET in kBq/ml/MBq/kg. | 5 years |
| The altered AV45-PET pattern in SCD/SCD-plus with progression. | Global SUVR change of brain of AV45-PET in kBq/ml/MBq/kg. | 5 years |
| Genotype of SCD/SCD-plus with progression. | ApoE genotype by blood test. | 5 years |
| AD7c-NTP level of SCD/SCD-plus with progression. | AD7c-NTP level by urine tests. | 5 years |
Not provided
Not provided
1. NC Inclusion Criteria:
2. SCD Inclusion Criteria:
3.SCD-plus Inclusion Criteria:
3. MCI Inclusion Criteria:
4. AD Inclusion Criteria The diagnosis of AD syndrome is based on the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA)with a total CDR score of 1.
Exclusion Criteria:
Not provided
Not provided
Volunteers recrewed from communities, and signed up with informed consent.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ying Han, Doctor | Xuanwu Hospitial Capital Medical University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Neurolgy,Xuanwu Hospital of Capital Medical University | Beijing | Beijing Municipality | 100053 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40404356 | Derived | Jiang X, Zhang M, Yan C, Daamen M, Boecker H, Yue F, Jessen F, Hu X, Han Y. Brain Topological Changes in Subjective Cognitive Decline and Associations with Amyloid Stages. J Neurosci. 2025 Jun 18;45(25):e2310242025. doi: 10.1523/JNEUROSCI.2310-24.2025. | |
| 40053120 | Derived | Chen HJ, Zhang M, Wei M, Yu X, Wang Y, Yang J, Li R, Zhao W, Wang X, Zhang S, Wang K, Bai T, Huo Y, Huang W, Dai Z, Ma G, Han Y, Chen G, Shu N. Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer's disease: insights from [18F]-florbetapir PET imaging. Eur J Nucl Med Mol Imaging. 2025 Jul;52(8):2929-2940. doi: 10.1007/s00259-025-07172-8. Epub 2025 Mar 7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Subjective Cognitive Decline plus, SCD-plus | The inclusion criteria for SCD-plus are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) concerns (worries) associated with memory complaint; and (3) failure to meet the following criteria for MCI. |
|
| Gut microbiota of SCD/SCD-plus with progression. | Gut microbiota level by 16s rDNA sequencing | 5 years |
| 39812690 | Derived | Zhao C, Li T, Hao S, Zhao L, Han Y, Cai Y. Dysregulation of the molecular clock by blood-borne factors in Alzheimer's disease patients. J Neurol. 2025 Jan 15;272(2):121. doi: 10.1007/s00415-024-12824-0. |
| 39710611 | Derived | Yu X, Zhang Y, Cai Y, Rong N, Li R, Shi R, Wei M, Jiang J, Han Y. Asymmetrical patterns of beta-amyloid deposition and cognitive changes in Alzheimer's disease: the SILCODE study. Cereb Cortex. 2024 Dec 3;34(12):bhae485. doi: 10.1093/cercor/bhae485. |
| 37740923 | Derived | Wang L, Xu H, Wang M, Brendel M, Rominger A, Shi K, Han Y, Jiang J. A metabolism-functional connectome sparse coupling method to reveal imaging markers for Alzheimer's disease based on simultaneous PET/MRI scans. Hum Brain Mapp. 2023 Dec 1;44(17):6020-6030. doi: 10.1002/hbm.26493. Epub 2023 Sep 23. |
| 37021284 | Derived | Wang T, Yao Y, Han C, Li T, Du W, Xue J, Han Y, Cai Y. MCP-1 levels in astrocyte-derived exosomes are changed in preclinical stage of Alzheimer's disease. Front Neurol. 2023 Mar 20;14:1119298. doi: 10.3389/fneur.2023.1119298. eCollection 2023. |
| 35387811 | Derived | Wang T, Wang X, Yao Y, Zhao C, Yang C, Han Y, Cai Y. Association of plasma apolipoproteins and levels of inflammation-related factors with different stages of Alzheimer's disease: a cross-sectional study. BMJ Open. 2022 Apr 6;12(4):e054347. doi: 10.1136/bmjopen-2021-054347. |
| 35164860 | Derived | Sheng C, Yang K, He B, Du W, Cai Y, Han Y. Combination of gut microbiota and plasma amyloid-beta as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study. Alzheimers Res Ther. 2022 Feb 14;14(1):35. doi: 10.1186/s13195-022-00977-x. |
| 34291850 | Derived | Ding C, Du W, Zhang Q, Wang L, Han Y, Jiang J. Coupling relationship between glucose and oxygen metabolisms to differentiate preclinical Alzheimer's disease and normal individuals. Hum Brain Mapp. 2021 Oct 15;42(15):5051-5062. doi: 10.1002/hbm.25599. Epub 2021 Jul 22. |
| 33827675 | Derived | Dong QY, Li TR, Jiang XY, Wang XN, Han Y, Jiang JH. Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population. Alzheimers Res Ther. 2021 Apr 7;13(1):74. doi: 10.1186/s13195-021-00811-w. |
| 32716355 | Derived | Sheng C, Sun Y, Wang M, Wang X, Liu Y, Pang D, Liu J, Bi X, Du W, Zhao M, Li Y, Li X, Jiang J, Han Y. Combining Visual Rating Scales for Medial Temporal Lobe Atrophy and Posterior Atrophy to Identify Amnestic Mild Cognitive Impairment from Cognitively Normal Older Adults: Evidence Based on Two Cohorts. J Alzheimers Dis. 2020;77(1):323-337. doi: 10.3233/JAD-200016. |
| 31350244 | Derived | Li X, Wang X, Su L, Hu X, Han Y. Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline. BMJ Open. 2019 Jul 26;9(7):e028188. doi: 10.1136/bmjopen-2018-028188. |
| 31159873 | Derived | Sun Y, Wang X, Wang Y, Dong H, Lu J, Scheininger T, Ewers M, Jessen F, Zuo XN, Han Y. Anxiety correlates with cortical surface area in subjective cognitive decline: APOE epsilon4 carriers versus APOE epsilon4 non-carriers. Alzheimers Res Ther. 2019 Jun 3;11(1):50. doi: 10.1186/s13195-019-0505-0. |